Skip to main content

Development of models to improve management of Myasthenia Gravis: From basic knowledge to clinical application

Objective

Autoimmune Myasthenia Gravis (MG) is a rare, chronic and heterogeneous neuromuscular disease characterised by severe muscle weakness. In most patients it is due to auto-antibodies to the acetylcholine receptor (AChR). The detrimental effects of the autoimmune attack on the muscle are not fully understood. The current treatments of MG induce severe side effects with no permanent clinical remission. The early-onset patients are mostly females with thymic hyperplasia, while the existing experimental model for MG (EAMG) does not present thymic pathology.

This proposal intends to develop models to progress in knowledge, monitoring, diagnosis and therapy of MG:
a) Videomicroscopic models to explore the motility of lymphocytes involved in thymic remodelling in young females
b) New transgenic models over-expressing CXCL13 chemokine in the thymus, to better mimic the human disease which involves thymic abnormalities
c) Mouse model of estrogen deficiency, to determine the influence of estrogens in predisposition and progression of MG
d) Humanized NOD/SCID mouse model transferred with human MG thymocytes to test therapy by human regulatory T cells
e) TCR based signature, for better classification and monitoring of MG patients
f) Rat EAMG models immunized with Torpedo AChR, to test an array of therapies (IVIg subfractions, chemokine inhibitors, regulatory cells
g) Rat models immunized with recombinant human AChR subunits, to determine the contribution of each subunit to the pathogenicity and develop immunotherapies
h) Monkey models to test protective anti-AChR antibodies.

This research conducted by 4 academic and 6 SME partners has the potential to develop new commercial products for the benefit of the patients. Since the research teams of this program participate in a large "European MG Network" supported by the EC, interactions between the two networks will promote efficient dissemination of the obtained knowledge.

Call for proposal

FP6-2005-LIFESCIHEALTH-7
See other projects for this call

Funding Scheme

STREP - Specific Targeted Research Project

Coordinator

UNIVERSITÉ PARIS-SUD
Address
15 Rue Georges Clémenceau
Orsay
France

Participants (9)

BIOKINE THERAPEUTICS LTD
Israel
Address
Weizmann Science Park, Building 13A
Rehovot
EPSILON-BIOTECH BVBA
Belgium
Address
Beverzakbroekweg 91
Zonhoven
GENMAB A/S
Denmark
Address
Toldbodgade 33
Copenhagen
HELLENIC PASTEUR INSTITUTE
Greece
Address
127 Vassilissis Sofias Avenue
Athens
IMMUNID
France
Address
43, Allée Des Romantiques
Grenoble
OMRIX BIOPHARMACEUTICALS LTD
Israel
Address
Weizmann Science Park, Bldg 14
Nes-ziona
REGULON AE
Greece
Address
Grigoriou Afxentiou 7, Alimos
Athens
UNIVERSITY OF MAASTRICHT
Netherlands
Address
Dr. Tanslaan 10
Maastricht
WEIZMANN INSTITUTE OF SCIENCE
Israel
Address
Herzl Street 2
Rehovot